Novo Nordisk A/S (NYSE:NVO) Receives Consensus Rating of “Moderate Buy” from Analysts

Novo Nordisk A/S (NYSE:NVO) has received an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $140.20.

NVO has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd.

Novo Nordisk A/S Stock Down 2.2 %

Shares of NVO opened at $83.19 on Wednesday. The company’s 50-day moving average price is $101.94 and its 200 day moving average price is $120.27. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market cap of $373.32 billion, a P/E ratio of 26.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Institutional Investors Weigh In On Novo Nordisk A/S

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its holdings in Novo Nordisk A/S by 0.4% in the second quarter. Rhumbline Advisers now owns 60,974 shares of the company’s stock valued at $8,703,000 after acquiring an additional 270 shares in the last quarter. Savant Capital LLC grew its stake in shares of Novo Nordisk A/S by 16.2% during the second quarter. Savant Capital LLC now owns 12,587 shares of the company’s stock worth $1,797,000 after purchasing an additional 1,751 shares in the last quarter. Strategic Financial Concepts LLC increased its holdings in Novo Nordisk A/S by 12,106.7% in the second quarter. Strategic Financial Concepts LLC now owns 206,172 shares of the company’s stock valued at $294,000 after buying an additional 204,483 shares during the last quarter. Ausdal Financial Partners Inc. increased its holdings in Novo Nordisk A/S by 6.7% in the second quarter. Ausdal Financial Partners Inc. now owns 3,641 shares of the company’s stock valued at $520,000 after buying an additional 230 shares during the last quarter. Finally, Cahill Financial Advisors Inc. raised its stake in Novo Nordisk A/S by 14.9% in the second quarter. Cahill Financial Advisors Inc. now owns 3,859 shares of the company’s stock valued at $551,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.